JP7075669B2 - 核酸送達用カチオン性脂質及びその調製物 - Google Patents
核酸送達用カチオン性脂質及びその調製物 Download PDFInfo
- Publication number
- JP7075669B2 JP7075669B2 JP2019522244A JP2019522244A JP7075669B2 JP 7075669 B2 JP7075669 B2 JP 7075669B2 JP 2019522244 A JP2019522244 A JP 2019522244A JP 2019522244 A JP2019522244 A JP 2019522244A JP 7075669 B2 JP7075669 B2 JP 7075669B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- lipid
- iia
- certain embodiments
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/20—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
- C07C211/22—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton containing at least two amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/10—Hydrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/10—Hydrazines
- C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
- C07C243/14—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/10—Hydrazines
- C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
- C07C243/16—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/02—Monothiocarbamic acids; Derivatives thereof
- C07C333/10—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups being part of any of the groups, X being a hetero atom, Y being any atom, e.g., N-acyl-thiocarbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662418844P | 2016-11-08 | 2016-11-08 | |
| US62/418,844 | 2016-11-08 | ||
| US201762507829P | 2017-05-18 | 2017-05-18 | |
| US62/507,829 | 2017-05-18 | ||
| PCT/IL2017/051212 WO2018087753A1 (en) | 2016-11-08 | 2017-11-07 | Cationic lipids for nucleic acid delivery and preparation thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020512272A JP2020512272A (ja) | 2020-04-23 |
| JP2020512272A5 JP2020512272A5 (cg-RX-API-DMAC10.html) | 2020-12-03 |
| JP7075669B2 true JP7075669B2 (ja) | 2022-05-26 |
Family
ID=62109569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522244A Active JP7075669B2 (ja) | 2016-11-08 | 2017-11-07 | 核酸送達用カチオン性脂質及びその調製物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11851389B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3538515B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7075669B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN110167922B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2017356699B2 (cg-RX-API-DMAC10.html) |
| DK (1) | DK3538515T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2928358T3 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2019005287A (cg-RX-API-DMAC10.html) |
| PT (1) | PT3538515T (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018087753A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108368028B (zh) | 2015-10-28 | 2021-09-03 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
| US12678515B2 (en) | 2015-12-30 | 2026-07-14 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| EP3484517B1 (en) | 2016-07-18 | 2025-07-02 | Ramot at Tel-Aviv University Ltd. | Modular platform for targeted therapeutics |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| ES2964547T3 (es) | 2018-06-08 | 2024-04-08 | Fujifilm Corp | Compuesto, sal del mismo y partículas lipídicas |
| MX2021003726A (es) | 2018-10-01 | 2021-05-13 | BioNTech SE | Particulas de arn que comprenden polisarcosina. |
| DK3864163T3 (da) | 2018-10-09 | 2024-05-06 | Univ British Columbia | Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed |
| CA3116576A1 (en) | 2018-10-18 | 2020-04-23 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| CA3117924A1 (en) * | 2018-11-13 | 2020-05-22 | Oncorus, Inc. | Encapsulated polynucleotides and methods of use |
| CN119285480A (zh) * | 2018-12-05 | 2025-01-10 | 英特利亚治疗股份有限公司 | 改性的胺脂质 |
| CA3143865A1 (en) * | 2019-06-07 | 2020-12-10 | Fujifilm Corporation | Lipid composition |
| EP4059505B1 (en) * | 2019-11-15 | 2024-02-21 | FUJIFILM Corporation | Lipid composition |
| US20230241223A1 (en) * | 2020-03-25 | 2023-08-03 | BioNTech SE | Rna particles comprising polysarcosine |
| TWI899203B (zh) | 2020-04-09 | 2025-10-01 | 大陸商蘇州艾博生物科技有限公司 | 脂質奈米粒子組成物 |
| WO2021204179A1 (en) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
| EP4153560A4 (en) * | 2020-05-19 | 2024-04-24 | Ramot at Tel-Aviv University Ltd. | LIPID PARTICLES FOR NUCLEIC ACID DELIVERY AND CLINICAL APPLICATIONS THEREOF |
| KR20230051172A (ko) | 2020-07-16 | 2023-04-17 | 아퀴타스 테라퓨틱스 인크. | 지질 나노 입자에 사용하기 위한 양이온성 지질 |
| WO2022066916A1 (en) * | 2020-09-23 | 2022-03-31 | Translate Bio, Inc. | Piperazine-based cationic lipids |
| CZ310613B6 (cs) * | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| WO2022112855A1 (en) * | 2020-11-27 | 2022-06-02 | Guangzhou Ribobio Co., Ltd | Lipid compound and the composition thereof |
| KR20230138496A (ko) * | 2021-02-02 | 2023-10-05 | 라모트 앳 텔-아비브 유니버시티 리미티드 | 핵산 전달에 적합한 지질 |
| CN117327270B (zh) * | 2021-04-08 | 2026-07-07 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用 |
| CN115197079A (zh) * | 2021-04-08 | 2022-10-18 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用 |
| JP2024518689A (ja) * | 2021-04-09 | 2024-05-02 | ファイザー・インク | 脂質を生産するための方法 |
| JP2024516164A (ja) * | 2021-04-22 | 2024-04-12 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 正確なインビボhdr介在性遺伝子編集を可能にするオールインワンデンドリマーベース脂質ナノ粒子 |
| CA3215963A1 (en) * | 2021-05-28 | 2022-12-01 | Yaoxin LIN | Lipid compound and use thereof in delivery of nucleic acid |
| EP4370134A4 (en) | 2021-07-13 | 2025-08-06 | Technion Res & Dev Foundation | COMPOSITIONS AND METHODS FOR TREATING A HEALTH CONDITION |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| EP4365168B1 (en) | 2021-07-23 | 2025-10-15 | Jenkem Technology Co., Ltd. (Tianjin) | Polyol-modified lipid compound and preparation method and application thereof |
| CN115010681A (zh) * | 2021-09-07 | 2022-09-06 | 安徽荣灿生物科技有限公司 | 一类阳离子脂质体分子及其制备和应用 |
| WO2023061460A1 (zh) * | 2021-10-15 | 2023-04-20 | 厦门赛诺邦格生物科技股份有限公司 | 含氮的阳离子脂质及其应用 |
| CN113999128B (zh) * | 2021-11-25 | 2024-05-10 | 苏州科锐迈德生物医药科技有限公司 | 脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
| CN120097855A (zh) * | 2021-12-31 | 2025-06-06 | 厦门赛诺邦格生物科技股份有限公司 | 一种侧链含功能性基团的阳离子脂质及其应用 |
| CN114213347B (zh) * | 2022-02-22 | 2022-05-20 | 中国科学院基础医学与肿瘤研究所(筹) | 一种双价可电离脂质化合物、组合物及其应用 |
| CN114213346B (zh) * | 2022-02-22 | 2022-05-20 | 中国科学院基础医学与肿瘤研究所(筹) | 一种双价可电离脂质化合物、组合物及其应用 |
| CN118804743A (zh) * | 2022-03-04 | 2024-10-18 | 益杰立科(上海)生物科技有限公司 | 靶向递送系统和方法 |
| CN114874146B (zh) * | 2022-03-25 | 2023-09-12 | 圣诺生物医药技术(苏州)有限公司 | 组氨酸脂质、组氨酸脂质纳米颗粒及其制备方法和应用 |
| CN116354836A (zh) * | 2022-03-25 | 2023-06-30 | 深圳市新合生物医疗科技有限公司 | 阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统 |
| EP4534525A4 (en) * | 2022-06-02 | 2025-08-20 | Xiamen Sinopeg Biotech Co Ltd | CATIONIC LIPID BASED ON AMINO ACIDS CONTAINING UNSATURATED BONDS |
| CN115557851B (zh) * | 2022-06-27 | 2023-04-18 | 上海云沂生物医药科技有限公司 | 一种氨基脂质、其合成方法、颗粒及用途 |
| CN118265692B (zh) * | 2022-09-09 | 2025-06-13 | 厦门赛诺邦格生物科技股份有限公司 | 一种碳核阳离子脂质 |
| IL321425A (en) | 2022-12-23 | 2025-08-01 | Biontech Delivery Tech Gmbh | compound |
| WO2024160826A1 (en) | 2023-01-31 | 2024-08-08 | BioNTech SE | Compositions and methods |
| CN116143707B (zh) * | 2023-02-24 | 2024-04-19 | 山东大学 | 一种碱基可电离脂质及其制备方法与应用 |
| CN117384055B (zh) * | 2023-04-27 | 2024-11-19 | 仁景(苏州)生物科技有限公司 | 用于递送治疗剂的可电离脂质及其用途 |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| EP4727917A1 (en) * | 2023-06-13 | 2026-04-22 | Ramot at Tel-Aviv University Ltd. | Biodegradable carbamate lipids with increased stability |
| WO2025027019A1 (en) | 2023-07-31 | 2025-02-06 | BioNTech SE | Method of determining nucleic acid concentration in aqueous solution or dispersion |
| CN117137885A (zh) * | 2023-08-29 | 2023-12-01 | 浙江大学 | 一种基于米屈肼衍生物的脂质纳米颗粒及其应用 |
| WO2025064850A1 (en) | 2023-09-22 | 2025-03-27 | BioNTech SE | Rna constructs with n-terminal degrons to enhance an immune response |
| TW202527962A (zh) | 2023-10-31 | 2025-07-16 | 德商拜恩技術股份公司 | 粒子、組合物及方法 |
| FR3155424A1 (fr) | 2023-11-15 | 2025-05-23 | BioNTech SE | Compositions immunogènes contre le sars-cov-2 |
| WO2025106754A1 (en) | 2023-11-15 | 2025-05-22 | BioNTech SE | Coronavirus vaccine |
| WO2025133105A1 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Compositions and methods |
| AU2024413489A1 (en) * | 2023-12-29 | 2026-07-16 | Samyang Biopharm Corporation | Nanoparticle composition for drug delivery |
| WO2025149492A1 (en) | 2024-01-08 | 2025-07-17 | BioNTech SE | Rna encoding an immune inhibitory il-1 family member |
| WO2025160118A1 (en) * | 2024-01-22 | 2025-07-31 | The Trustees Of The University Of Pennsylvania | Compositions and methods for hematopoietic stem cell (hsc) targeted delivery of therapeutic agents |
| WO2025176732A1 (en) | 2024-02-20 | 2025-08-28 | BioNTech SE | Compositions and methods |
| WO2025215636A1 (en) | 2024-04-08 | 2025-10-16 | Yeda Research And Development Co. Ltd. | Anti-defense system polypeptides and uses thereof |
| WO2025228979A1 (en) | 2024-04-30 | 2025-11-06 | Neovac Ltd. | Lipids nanoparticle formulations suitable for lung targeting |
| WO2025245869A1 (zh) * | 2024-05-31 | 2025-12-04 | 清华大学 | 含有精氨酸结构的可电离脂质分子、包含其的脂质纳米颗粒及其用途 |
| WO2025261607A1 (en) | 2024-06-21 | 2025-12-26 | BioNTech SE | Particles, compositions and methods |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026009227A1 (en) | 2024-07-04 | 2026-01-08 | Yeda Research And Development Co. Ltd. | Compositions for downregulating zeb2 in macrophages and uses thereof |
| WO2026013059A1 (en) | 2024-07-08 | 2026-01-15 | Neovac Ltd. | Nanoparticle formulations for treatment of inflammations |
| WO2026021698A1 (en) | 2024-07-23 | 2026-01-29 | BioNTech SE | Nucleic acid particle |
| WO2026047603A1 (en) | 2024-08-28 | 2026-03-05 | BioNTech SE | Sars-cov-2 immunogenic compositions |
| WO2026047148A1 (en) | 2024-08-29 | 2026-03-05 | BioNTech SE | Minimal polypeptide-encoding rnas |
| WO2026057626A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having multiple enzymatically active domains |
| WO2026057625A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having a chap domain with engineered active site |
| WO2026068864A1 (en) | 2024-09-30 | 2026-04-02 | BioNTech SE | Engineered ch1 and cl domains for the prevention of chain mispairing |
| WO2026082899A2 (en) | 2024-10-16 | 2026-04-23 | BioNTech SE | Rna for preventing or treating tuberculosis |
| WO2026109749A1 (en) | 2024-11-24 | 2026-05-28 | Neovac Ltd. | Ionizable lipids suitable for nucleic acid delivery |
| WO2026109750A1 (en) | 2024-11-24 | 2026-05-28 | Neovac Ltd. | Ionizable lipids useful in nucleic acid delivery |
| WO2026119817A1 (en) | 2024-12-02 | 2026-06-11 | BioNTech SE | Agents and methods for targeted delivery of immune effector cells |
| WO2026125590A1 (en) | 2024-12-13 | 2026-06-18 | BioNTech SE | Measuring nucleic acid integrity |
| WO2026125598A1 (en) | 2024-12-13 | 2026-06-18 | BioNTech SE | Measuring nucleic acid integrity |
| WO2026148356A1 (en) | 2025-01-06 | 2026-07-09 | BioNTech SE | Coronavirus and influenza immunogenic combinations |
| WO2026150132A1 (en) | 2025-01-12 | 2026-07-16 | BioNTech SE | Combination therapy comprising an rna cancer vaccine and a multispecific binding agent targeting pd-1/pd-l1 and vegf/vegfr for cancer treatment |
| WO2026162682A1 (en) | 2025-01-29 | 2026-08-06 | BioNTech SE | Compositions for delivery of plasmodium rh5 antigens and related methods |
| WO2026162552A1 (en) | 2025-01-31 | 2026-08-06 | BioNTech SE | Agents and methods for targeted delivery to cells |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006111982A1 (en) | 2005-04-21 | 2006-10-26 | National Research Development Corporation | A process for producing modified reconstituted sendai viral envelope specific for drug and/or gene delivery to liver cells |
| JP2012508264A (ja) | 2008-11-10 | 2012-04-05 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | 治療薬を送達するための新規な脂質及び組成物 |
| WO2014007398A1 (ja) | 2012-07-06 | 2014-01-09 | 協和発酵キリン株式会社 | カチオン性脂質 |
| WO2016021673A1 (ja) | 2014-08-06 | 2016-02-11 | 協和発酵キリン株式会社 | small RNA含有医薬組成物の薬効を予測する方法 |
| WO2016176330A1 (en) | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL58413C (cg-RX-API-DMAC10.html) * | 1941-12-04 | |||
| US3703554A (en) * | 1969-07-22 | 1972-11-21 | Scm Corp | Terpenylamino ethers and thioethers |
| GB1367089A (en) * | 1970-07-23 | 1974-09-18 | Marumo H | Surface modifier for synthetic high polymers |
| US4034040A (en) * | 1971-05-24 | 1977-07-05 | Pfizer Inc. | Xylene-diamines as antiviral agents |
| FR2687398B1 (fr) * | 1992-02-17 | 1994-04-29 | Oreal | Monomeres betauiniques, polymeres correspondants ainsi que leur utilisation, et procedes de preparation y relatifs. |
| JP3544429B2 (ja) * | 1996-04-25 | 2004-07-21 | 三菱製紙株式会社 | 可逆性感熱記録材料 |
| CN102665761A (zh) | 2009-11-04 | 2012-09-12 | 玛瑞纳生物技术有限公司 | 活性产生递送分子 |
| WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
| CA2953341C (en) * | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| CN108368028B (zh) | 2015-10-28 | 2021-09-03 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
-
2017
- 2017-11-07 WO PCT/IL2017/051212 patent/WO2018087753A1/en not_active Ceased
- 2017-11-07 EP EP17869620.9A patent/EP3538515B1/en active Active
- 2017-11-07 DK DK17869620.9T patent/DK3538515T3/da active
- 2017-11-07 CN CN201780082052.XA patent/CN110167922B/zh active Active
- 2017-11-07 MX MX2019005287A patent/MX2019005287A/es unknown
- 2017-11-07 PT PT178696209T patent/PT3538515T/pt unknown
- 2017-11-07 ES ES17869620T patent/ES2928358T3/es active Active
- 2017-11-07 US US16/347,995 patent/US11851389B2/en active Active
- 2017-11-07 JP JP2019522244A patent/JP7075669B2/ja active Active
- 2017-11-07 AU AU2017356699A patent/AU2017356699B2/en active Active
-
2023
- 2023-10-18 US US18/489,240 patent/US20240246898A1/en active Pending
-
2024
- 2024-10-21 US US18/921,310 patent/US20250162978A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006111982A1 (en) | 2005-04-21 | 2006-10-26 | National Research Development Corporation | A process for producing modified reconstituted sendai viral envelope specific for drug and/or gene delivery to liver cells |
| JP2012508264A (ja) | 2008-11-10 | 2012-04-05 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | 治療薬を送達するための新規な脂質及び組成物 |
| WO2014007398A1 (ja) | 2012-07-06 | 2014-01-09 | 協和発酵キリン株式会社 | カチオン性脂質 |
| WO2016021673A1 (ja) | 2014-08-06 | 2016-02-11 | 協和発酵キリン株式会社 | small RNA含有医薬組成物の薬効を予測する方法 |
| WO2016176330A1 (en) | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
Non-Patent Citations (1)
| Title |
|---|
| DATABASE REGISTRY on STN,2008年,RN 1027464-32-9 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2928358T3 (es) | 2022-11-17 |
| JP2020512272A (ja) | 2020-04-23 |
| PT3538515T (pt) | 2022-09-30 |
| EP3538515A4 (en) | 2020-07-08 |
| WO2018087753A1 (en) | 2018-05-17 |
| DK3538515T3 (da) | 2022-10-17 |
| US11851389B2 (en) | 2023-12-26 |
| CN110167922B (zh) | 2023-09-19 |
| MX2019005287A (es) | 2019-10-14 |
| AU2017356699A1 (en) | 2019-04-18 |
| US20240246898A1 (en) | 2024-07-25 |
| US20190292130A1 (en) | 2019-09-26 |
| EP3538515A1 (en) | 2019-09-18 |
| AU2017356699B2 (en) | 2021-11-11 |
| EP3538515B1 (en) | 2022-07-20 |
| US20250162978A1 (en) | 2025-05-22 |
| CA3039137A1 (en) | 2018-05-17 |
| CN110167922A (zh) | 2019-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240246898A1 (en) | Cationic lipids for nucleic acid delivery and preparation thereof | |
| JP6182457B2 (ja) | カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子 | |
| JP6948313B2 (ja) | 治療剤の細胞内送達のための化合物および組成物 | |
| KR20230138496A (ko) | 핵산 전달에 적합한 지질 | |
| CN101842347B (zh) | 阳离子脂质、其制备方法以及包含其的输送系统 | |
| CN110974981A (zh) | 用于递送信使rna的组合物和方法 | |
| KR20170075742A (ko) | B형 간염 바이러스 유전자 발현을 제거하는 조성물 및 방법 | |
| CN104603102A (zh) | 阳离子性脂质 | |
| CA3215957A1 (en) | Tissue-specific nucleic acid delivery by mixed cationic lipid particles | |
| WO2018225871A1 (ja) | カチオン性脂質としての化合物 | |
| JP2023521516A (ja) | 効率的な核酸送達のための担体 | |
| WO2017010573A1 (ja) | β2GPI遺伝子発現抑制RNAi医薬組成物 | |
| JP7657773B2 (ja) | 核酸送達のための脂質化カチオン性ペプチド-peg組成物 | |
| WO2016002753A1 (ja) | カチオン性脂質 | |
| KR100909786B1 (ko) | 올리고 펩티드를 수식한 신규한 양이온성 지질, 그의 제조 방법 및 그를 포함하는 전달체 | |
| JP6774965B2 (ja) | カチオン性脂質としての化合物 | |
| CA3039137C (en) | Cationic lipids for nucleic acid delivery and preparation thereof | |
| JP7043411B2 (ja) | カチオン性脂質としての化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201023 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201023 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210826 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210907 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211206 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220412 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220509 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7075669 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |